Globe Newswire

Spectral Medical Provides April Tigris Trial Update May 6, 2024 07:30AM

•   105 patients enrolled

•   April represents a record breaking month for patient enrollment 

TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized... (continue reading...)

Metasphere Labs Announces a Follow-Up Event Regarding Bitcoin’s Defi Revolution May 6, 2024 07:30AM

VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. ("Metasphere" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is delighted to announce a follow-up event tailored for those who were unable to attend the initial sessions, in response to the overwhelming demand and overcapacity of our recent seminar on Bitcoin's DeFi revolution. Additionally, the Company excited to open limited registration spots for new registrants eager... (continue reading...)

Tyson Foods Reports Second Quarter 2024 Results May 6, 2024 07:30AM

SPRINGDALE, Ark., May 06, 2024 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, reported the following results:                                         

(in millions, except per share data)Second Quarter Six Months... (continue reading...)

Plus Therapeutics Announces Private Placement Financing of up to $18 Million May 6, 2024 07:30AM

AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it has entered into a securities purchase agreement with new institutional investors and Company insiders to raise up to approximately $18 million in gross proceeds, including initial... (continue reading...)

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences May 6, 2024 07:30AM

BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it will participate at two investor conferences in... (continue reading...)